ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1576

Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis

Umar Ghaffar1, Hannah Langenfeld2, Cynthia Crowson3, Tanaz Kermani4, Michelle Burke1, Boyd Viers1, Aaron Potretzke1, Haraldur Bjarnason1, Kenneth J. Warrington1 and Matthew J. Koster1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4University of California Los Angeles, West Hills, CA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, IgG4 Related Disease, Smoking, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort.

Methods: Using a proprietary medical text search algorithm, all patients from 1/1/1996 to 12/31/2019 with mention of ‘periaortitis,’ ‘periaortic soft tissue,’ or ‘retroperitoneal fibrosis’ in the medical chart were screened. Patients with radiographic confirmation of infra-renal abdominal aorta (irAbAo) periaortitis were included. Cases with soft tissue thickening elsewhere were excluded unless they had concomitant irAbAo periaortitis. Patients were further characterized based on presence/absence of aneurysm and associated conditions (Table 1). Cox models were used to examine associations between patient characteristics and outcomes.

Results: 2,507 charts were manually reviewed and 495 patients were identified: 326 (66%) male, 403 (81%) white and 70% (307/436) current or former smokers (Table 2). Mean (SD) age at diagnosis was 57.4 (11.7) years. Most common features at presentation included abdominal pain (44%), back pain (40%), renal insufficiency (36%). End-stage renal disease (ESRD) was present in 52 (12%) at diagnosis. Ureteral stents were placed in 236 (48%): unilateral (n=93), bilateral (n=143). Percutaneous nephrostomy tubes were used in 50 patients, 20 due to stent failure or pain. Treatments utilized are listed in Table 2. Prednisone was given in 346 (70%); 79 as monotherapy. The most common steroid-sparing treatments included tamoxifen, methotrexate, and mycophenolate. At last visit, 160 patients were still on prednisone, 57 on tamoxifen and 129 on other immunosuppressive medication. Repeat imaging was available in 455 patients which showed resolution of periaortic thickening in 40 (9%), improvement in 261 (57%), no change in 103 (23%), and worsening in 51 (11%). Of 212 patients with stents and follow-up data, 141 had successful permanent removal. Of patients with nephrostomy tubes, 33 had permanent removal. Compared to baseline, renal function stage at last follow up was improved in 39%, worse in 19% and stayed the same in 42%. Only one patient without ESRD at baseline developed ESRD by last follow-up. Of those with non-aneurysmal irAbAo periaortitis at baseline, only 8% developed aneurysm after presentation. For patients with aneurysm at diagnosis, 14 had intervention, 2 had AbAo rupture. No evaluated factors were associated with likelihood of ureteral stent removal. Factors significantly associated with prednisone discontinuation and radiographic resolution are listed in Table 3.

Conclusion: In this large cohort of patients with chronic abdominal periaortitis, over half had radiographic improvement but resolution was uncommon. Older age at diagnosis and presence of secondary cause were associated with increased likelihood of resolution. Smokers had two times lower likelihood of radiographic resolution. Two-thirds were able to achieve permanent ureteral stent extraction. Among patients without baseline aneurysm, subsequent development is rare. Treatment regimens were variable. Prospective studies are needed to determine which medications led to optimal outcomes.

Supporting image 1

Table 1: Category and sub-category definitions of periaortitis

Supporting image 2

Table 2: Chronic Periaortitis patient characteristics

Supporting image 3

Table 3: Factors associated with outcomes of interest


Disclosures: U. Ghaffar, None; H. Langenfeld, None; C. Crowson, None; T. Kermani, None; M. Burke, None; B. Viers, None; A. Potretzke, None; H. Bjarnason, None; K. Warrington, Eli Lilly, GlaxoSmithKlein(GSK), Kiniksa, Chemocentryx; M. Koster, None.

To cite this abstract in AMA style:

Ghaffar U, Langenfeld H, Crowson C, Kermani T, Burke M, Viers B, Potretzke A, Bjarnason H, Warrington K, Koster M. Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/clinical-presentation-and-outcome-of-patients-with-chronic-abdominal-periaortitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-presentation-and-outcome-of-patients-with-chronic-abdominal-periaortitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology